Paper40947993
Prospective Comparative Evaluation of the Xpert MTB/RIF and Xpert MTB/RIF Ultra Assays for Detecting Mycobacterium tuberculosis and Rifampin Resistance in High-resource, Intermediate-burden Settings.
Suh E and 6 others. Ann Lab Med, 2025. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Prospective Comparative Evaluation of the Xpert MTB/RIF and Xpert MTB/RIF Ultra Assays for Detecting Mycobacterium tuberculosis and Rifampin Resistance in High-resource, Intermediate-burden Settings. Papers, record 40947993. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40947993
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Prospective Comparative Evaluation of the Xpert MTB/RIF and Xpert MTB/RIF Ultra Assays for Detecting Mycobacterium tuberculosis and Rifampin Resistance in High-resource, Intermediate-burden Settings.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Mycobacterium tuberculosis | Major topic |
| Rifampin | Major topic |
| Drug Resistance, Bacterial | Major topic |
| Tuberculosis | Major topic |
| Humans | |
| Prospective Studies | |
| Sensitivity and Specificity | |
| DNA-Directed RNA Polymerases | |
| Mutation | |
| Bacterial Proteins | |
| DNA, Bacterial | |
| Antibiotics, Antitubercular | |
| Microbial Sensitivity Tests |
Source PubMed
References25
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37787077 | Evidence for Tuberculosis in Individuals With Xpert Ultra "Trace" Sputum During Screening of High-Burden Communities. | Clin Infect Dis | 2024 | https://conductscience.org/library/papers/37787077 | PubMed |
| 2 | 10764337 | Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. | Am J Respir Crit Care Med | 2000 | https://conductscience.org/library/papers/10764337 | PubMed |
| 3 | 31173647 | Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. | Cochrane Database Syst Rev | 2019 | https://conductscience.org/library/papers/31173647 | PubMed |
| 4 | 37452349 | GeneXpert MTB/RIF Ultra performance to detect uncommon rpoB mutations in Mycobacterium tuberculosis. | BMC Res Notes | 2023 | https://conductscience.org/library/papers/37452349 | PubMed |
| 5 | 35471095 | Diagnostic Performance of Xpert MTB/RIF Ultra Compared with Predecessor Test, Xpert MTB/RIF, in a Low TB Incidence Setting: a Retrospective Service Evaluation. | Microbiol Spectr | 2022 | https://conductscience.org/library/papers/35471095 | PubMed |
| 6 | 36602360 | Performance Evaluation of the BACTEC MGIT 960 System for Rifampin Drug-Susceptibility Testing of Mycobacterium tuberculosis Using the Current WHO Critical Concentration. | J Clin Microbiol | 2023 | https://conductscience.org/library/papers/36602360 | PubMed |
| 7 | 30728191 | Heat Inactivation Renders Sputum Safe and Preserves Mycobacterium tuberculosis RNA for Downstream Molecular Tests. | J Clin Microbiol | 2019 | https://conductscience.org/library/papers/30728191 | PubMed |
| 8 | 35876568 | The Practical Value of Xpert MTB/RIF Ultra for Diagnosis of Pulmonary Tuberculosis in a High Tuberculosis Burden Setting: a Prospective Multicenter Diagnostic Accuracy Study. | Microbiol Spectr | 2022 | https://conductscience.org/library/papers/35876568 | PubMed |
| 9 | 22779067 | Rapid diagnosis of tuberculosis and multidrug resistance using a MGIT 960 system. | Ann Lab Med | 2012 | https://conductscience.org/library/papers/22779067 | PubMed |
| 10 | 28851844 | The New Xpert MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing. | mBio | 2017 | https://conductscience.org/library/papers/28851844 | PubMed |
| 11 | 33616229 | Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis. | Cochrane Database Syst Rev | 2021 | https://conductscience.org/library/papers/33616229 | PubMed |
| 12 | 12354807 | The efficacy of the heat killing of Mycobacterium tuberculosis. | J Clin Pathol | 2002 | https://conductscience.org/library/papers/12354807 | PubMed |
| 13 | 32619114 | Head-to-head comparison of the diagnostic accuracy of Xpert MTB/RIF and Xpert MTB/RIF Ultra for tuberculosis: a meta-analysis. | Infect Dis (Lond) | 2020 | https://conductscience.org/library/papers/32619114 | PubMed |
| 14 | 39832887 | Real-world clinical utility of Xpert MTB/RIF Ultra in the assessment of tuberculosis in a low-TB-incidence, high-resource setting. | BMJ Open Respir Res | 2025 | https://conductscience.org/library/papers/39832887 | PubMed |
| 15 | 33130504 | Performance of Xpert MTB/RIF Ultra assay on respiratory and extra-respiratory samples in a high-resource setting with a low tuberculosis prevalence. | Diagn Microbiol Infect Dis | 2021 | https://conductscience.org/library/papers/33130504 | PubMed |
| 16 | 33317678 | Systematic rifampicin resistance errors with Xpert® MTB/RIF Ultra: implications for regulation of genotypic assays. | Int J Tuberc Lung Dis | 2020 | https://conductscience.org/library/papers/33317678 | PubMed |
| 17 | 20825313 | Rapid molecular detection of tuberculosis and rifampin resistance. | N Engl J Med | 2010 | https://conductscience.org/library/papers/20825313 | PubMed |
| 18 | 30928564 | The rapid molecular test Xpert MTB/RIF ultra: towards improved tuberculosis diagnosis and rifampicin resistance detection. | Clin Microbiol Infect | 2019 | https://conductscience.org/library/papers/30928564 | PubMed |
| 19 | 39754613 | Diagnostic accuracy of Xpert MTB/RIF Ultra for detecting pulmonary tuberculosis and rifampicin resistance: a systematic review and meta-analysis. | Eur J Clin Microbiol Infect Dis | 2025 | https://conductscience.org/library/papers/39754613 | PubMed |
| 20 | 24819214 | Mycobacterium tuberculosis persistence in various adipose depots of infected mice and the effect of anti-tubercular therapy. | Microbes Infect | 2014 | https://conductscience.org/library/papers/24819214 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42219539 | Bridging Genotypic and Phenotypic Drug Susceptibility Testing for Mycobacterium tuberculosis: A Baseline Prior to the Widespread Use of New and Repurposed Anti-Tuberculosis Drugs. | Ann Lab Med | 2026 | https://conductscience.org/library/papers/42219539 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40947993
GET https://conductscience.org/api/papers/v1/40947993/references?page=2